Haleon
- Market cap
- 39.67B
- P/E (TTM)i
- 18.87
- P/Bi
- 1.83
- EPSi
- 0.49
- Div yieldi
- 2.11%
- 52W posi
- 17%
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Fair Value how this is computed
- Implied fair-value range of 9.69-14.30, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is -24.8% below the average-multiple fair value of 12.00.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Haleon (HLN) | 39.67B | 18.87 | 1.83 | 2.11% |
| Takeda Pharmaceutical (TAK) | 58.68B | -55.67 | 1.23 | 3.26% |
| Teva Pharmaceutical Industries (TEVA) | 45.70B | 65.30 | 5.89 | 0.00% |
| Zoetis (ZTS) | 29.57B | 11.67 | 9.39 | 2.88% |
| United Therapeutics (UTHR) | 23.38B | 19.53 | 3.65 | 0.00% |
| Viatris (VTRS) | 20.09B | -47.27 | 1.41 | 2.74% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 15.9% below Morningstar's fair value estimate.
Fair value
Haleon PLC receives a 5-star quantitative star rating, indicating our belief that this share class offers a compelling opportunity for investors. The stock currently trades at a 14% discount to our quantitative fair value estimate of $10.45 per share, which is reinforced by this estimate's low uncertainty rating.
The firm's profitability increases our estimated valuation. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its enterprise value to free cash flow ratio of 18.9, which sits in the bottom 40% globally. This can be a sign of operational efficiency and potential for the company to fund growth, pay dividends, or reduce debt without needing additional capital. We believe this is a sign that shares could be cheap.
The firm's liquidity is an additional encouraging factor. Adequate liquidity allows a company to meet short-term obligations, enhancing financial stability and reducing distress risk. The firm's median trading volume over the past 60 days, a core component of liquidity, falls in the top 10% compared with global peers. Trading volumes are high on shares, which may indicate increased institutional interest in stock ownership. This characteristic further promotes our favorable price/fair value ratio.
Economic moat
The company's wide quantitative moat rating suggests a strong ability to maintain superior profitability thanks to competitive advantages that could persist up to two decades. This is supported by the company's strong financial health score, which indicates a low likelihood that the company will tumble into financial distress.
By Quantitative Equity Report
Quote time 2026-10-08 07:38:25 · For reference only, not investment advice and not tailored to your situation.